Skip to main content
Veterinary Medicines

ZOLETIL 50 (25 MG/ML + 25 MG/ML) LYOPHILISATE AND SOLVENT FOR SOLUTION FOR INJECTION FOR DOGS AND CATS

Authorised
  • Tiletamine hydrochloride
  • Water for injection
  • Zolazepam hydrochloride

Product identification

Medicine name:
ZOLETIL 50 (25 MG/ML + 25 MG/ML) LYOPHILISATE AND SOLVENT FOR SOLUTION FOR INJECTION FOR DOGS AND CATS
Active substance:
  • Tiletamine hydrochloride
  • Water for injection
  • Zolazepam hydrochloride
Target species:
  • Dog
  • Cat
Route of administration:
  • Intramuscular use
  • Intravenous use

Product details

Active substance and strength:
  • Tiletamine hydrochloride
    145.43
    milligram(s)
    /
    1.00
    Bottle
  • Water for injection
    5.00
    millilitre(s)
    /
    1.00
    Bottle
  • Zolazepam hydrochloride
    140.94
    milligram(s)
    /
    1.00
    Bottle
Pharmaceutical form:
  • Lyophilisate and solvent for solution for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Dog
    • Cat
  • Intravenous use
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QN01AX99
Authorisation status:
  • Valid
Authorised in:
  • France
Available in:
  • France
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • National Veterinary Medicines Agency
Authorisation number:
  • FR/V/7978320 6/2016
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0283/001
Concerned member states:
  • Finland
  • Ireland
  • Malta
  • Netherlands
  • Poland
  • Sweden

Documents

Summary of Product Characteristics

English (PDF)
Published on: 25/01/2023
Download
French (PDF)
Published on: 10/02/2023

Package Leaflet and Labelling

English (PDF)
Published on: 19/02/2024
Download
French (PDF)
Published on: 10/02/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."